VXA-G1.1-NN
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Infections
Conditions
Norovirus Infections
Trial Timeline
Apr 30, 2021 → Feb 16, 2022
NCT ID
NCT04875676About VXA-G1.1-NN
VXA-G1.1-NN is a phase 1/2 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04875676. Target conditions include Norovirus Infections.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05213728 | Phase 1 | Completed |
| NCT04875676 | Phase 1/2 | Completed |
Competing Products
11 competing products in Norovirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 25 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 33 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 44 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 25 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 33 |